DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Rossari Biotech Limited — Board Meeting Intimation

NSE 2 hrs ago·9 Oct 2026, 2:34 pm

Rossari Biotech

Rossari Biotech has announced that its board will meet on October 17, 2026, to review and approve the company's unaudited financial results for the first half of the fiscal year ending September 2026. This is a standard corporate procedure that allows the board to formally accept the financial data prepared by the management before it is made public.

For investors, this update is a key milestone, as the results will provide fresh insights into the company's operational performance and financial health during the interim period. The data will help the market assess the current trajectory of the business and its ability to meet its targets.

Investors should monitor the announcement for details on revenue growth, margins, and any commentary from the management regarding future outlook. This information will be crucial for evaluating the stock's short-term momentum and long-term investment potential.